ClinicalTrials.gg
CompletedNCT01177774NewTicsUpdated Nov 27, 2023

Assessment of Children With Tic Onset in the Past 6 Months

An observational study in Tourette Syndrome, Tourette's Disorder and Chronic Motor or Vocal Tic Disorder, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to participants aged 5 Years to 10 Years. Per ClinicalTrials.gov, last updated 2023-11-27.

Sponsored by Washington University School of Medicine · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
99
Ages
5 Years to 10 Years
Sex
All
01

Study summary

The purpose of this research is to study why most children who have tics never develop Tourette syndrome but some do. In other words, we aim to find features that may predict whose tics will go away and whose tics will continue or worsen, in children ages 5 through 10 years whose first tic occurred within the past 9 months.

Read the detailed description

Up to 30% of all children will have a tic at some point. However, tics that last a whole year (or more) occur in only 3% of the population. Thus tic persistence may be more unusual than tic onset, yet almost no data exist on which people with recent-onset tics go on to be diagnosable with Tourette syndrome or chronic tic disorder, versus those whose tics are only transient.

The overall goal of this research is to identify, prospectively, what imaging, clinical or neuropsychological features of children who just recently started ticcing will go on to develop a chronic tic disorder (including Tourette syndrome). Hypotheses are derived primarily from studies of patients with established tic disorders.

Aim 1. Study pathophysiology of recent-onset tics. Aim 1a. Identify clinical, neuropsychological, and brain imaging features that differentiate children with recent tic onset ("New Tics" group) from tic-free controls. We will test a priori hypotheses including tic suppression, inattentiveness, caudate nucleus volume, tic severity, and premonitory urges (see "Summary of hypotheses" on the 3rd page of Research Strategy). Secondary analyses will apply support vector machine (SVM) learning to a rich set of data to discover novel, multivariate differences in the New Tics group [3,45]. These data will also include tic phenomenology, psychiatric diagnosis, habit learning, motor dexterity, structural MRI, perfusion MRI, and resting state functional connectivity fMRI (rs-fcMRI).

Aim 1b. Compare New Tics subjects to a group of children who are matched for age but have already had tics for ≥1 year ("Existing TS/CTD"). Since both groups have tics, this comparison will highlight abnormalities that cannot be explained by the mere current presence of tics, including markers of chronicity or adaptation.

Aim 2. Prospective study of tic remission. We will re-evaluate New Tics subjects at the 1-year anniversary of tic onset (the accepted duration criterion for diagnosis of TS/CTD). Our pilot data show good variability in the change in tic symptom severity (i.e., change in YGTSS total tic score from baseline to followup: ΔTTS), so ΔTTS will be the primary dependent variable. We focus on outcome as a continuous variable because no reliable estimate exists for how many New Tics subjects will remit versus go on to diagnosis with TS/CTD. Remission rate also depends on definition and on the thoroughness of the follow-up evaluation [4].

Aim 2a. Study the physiology of tic remission by identifying changes in clinical, neuropsychological, and brain imaging variables that correlate with changes in clinical tic severity (ΔTTS). This Aim benefits from prospective observation and within-subject comparisons. The primary analysis will focus on any markers identified in Aim 1. A secondary analysis will apply machine learning methods for a data-driven approach (support vector regression: SVR).

Aim 2b. Identify predictors of improvement or worsening, i.e. clinical, neuropsychological, and brain imaging features at study entry that correlate significantly with ΔTTS. The 2 primary analyses will relate clinical outcome (ΔTTS) to tic suppression ability and caudate volume at study entry. Secondary analyses will examine other predictors using an SVR machine learning approach.

02

Conditions studied

  • Tourette Syndrome
  • Tourette's Disorder
  • Chronic Motor or Vocal Tic Disorder
  • Transient Tic Disorder
  • Tic Disorders
  • Provisional Tic Disorder

Keywords

  • functional connectivity MRI
  • brain volumetry
  • negative reinforcement
  • OCD
  • ADHD
03

In context

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

This study's enrollment of 99 is above the median of 60 across 46 observational studies indexed under Tourette Syndrome.

Browse Tourette Syndrome studies →

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,803 studies on the registry; 271 are open to participants now.

Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  1. A convenience sample of children age 5-10 who have tics now but whose first-ever tic occurred within the past 9 months. Subjects will be a convenience sample from community and clinical sources.
  2. A control group who already meets criteria for a diagnosis of a chronic tic disorder, matched for age, sex, handedness, and ADHD
  3. A control group who has no tics, matched for age, sex, handedness, and ADHD

Eligibility criteria

** All subjects **

Inclusion Criteria:

  • Age 5-10
  • from a parent and assent from the child.

    • New Tics Group **

Inclusion Criteria:

  • tics now, but developed them only in the past 9 months.

Exclusion criteria: secondary tics, another neurological disorder (not counting migraine), structural brain disease, severe systemic illness, nonproficiency in the English language, and psychiatric illness including mental retardation, autism, substance dependence, current substance abuse, primary psychotic illness, bipolar disorder and current major depression. Psychoactive medications are allowed if their dose has not changed in the past month.

** Existing TS/CTD control group **

Inclusion criteria:

  • children who meet criteria for Tourette's Disorder or Persistent Tic Disorder at enrollment
  • matched to children from the New Tics group on age (within 1 year), sex, handedness, and ADHD status.

Exclusion criteria: same as for the New Tics group.

** Tic-free controls **

Inclusion criteria: tic-free children matched to children from the New Tics group on age (within 1 year), sex, handedness, and ADHD status.

Exclusion criteria: current or past tic disorder in the subject or a first-degree relative, plus the exclusions listed for the New Tics group.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
99 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Recent-onset tics that will persist

    Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who, when reassessed at 1 year after the first tic began (i.e. 6-12 months after study enrollment) will turn out to meet criteria for a chronic tic disorder (including Tourette syndrome). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).

  • Recent-onset tics that will remit

    Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who will no longer have tics when reassessed 1 year after the first tic began (6 to 12 months after study enrollment). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).

  • Tic-free control subjects

    Children with no current or past tic disorder of similar age, sex and handedness as the children in the recent-onset tics groups.

  • Existing TS/CTD

    Children with current tics whose first tics were more than 12 months ago (DSM-5 Tourette's Disorder or Persistent \[Chronic\] Motor or Phonic Tic Disorder), of similar age, sex and handedness as the children in the recent-onset tics groups.

06

What researchers measure

Primary outcomes

  1. DSM-5 diagnosis of a chronic tic disorder at 12 months

    Research diagnosis of a chronic tic disorder at 12 months (cases), versus those whose tics are absent at 12 months (controls), will define two groups who will be compared on their baseline status (almost a year earlier) on a quantitative measure of functional connectivity maturity, pre-tic BOLD signal, caudate nucleus volume, and several clinical and neuropsychological measures.

    Time frame: 1 year after the onset of tics (6-12 months after the first study visit)

07

Study locations

1 site
  • Washington University School of Medicine, Movement Disorder Clinic
    Saint Louis, Missouri 63110, United States
08

References and documents

Individual participant data

Plan to share: Yes — Beginning in June, 2017, all data other than PHI will follow the NIMH RDoC data sharing policy.

Time frame: Subject-level data: first data upload approximately 25 September 2018, then twice yearly through the end of the grant period.

Access criteria: open

Data sharing details ↗ · ndar.nih.gov

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Jul 2023 and a completion of Jul 2023. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2010
First posted
Aug 9, 2010
Start
Aug 2010
Primary completionActual
Jul 13, 2023
CompletionActual
Jul 13, 2023
Last update
Nov 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01177774
Responsible party
Kevin J. Black, M.D. (Professor, Washington University School of Medicine) — Principal investigator
First posted
Aug 9, 2010
Start date
Aug 2010
Primary completion
Jul 13, 2023
Completion
Jul 13, 2023
Last update
Nov 27, 2023

Study contacts

Kevin J. Black, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion